Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Epigenica AB is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner, ensuring a focused prosecution environment. The administrative scope is similarly narrow, with the activity occurring in 1 distinct art unit. This concentration suggests that the company's current USPTO engagement is limited to a specific technical niche within the biotechnology sector.
LAFAVE, ELIZABETH ROSE is the busiest examiner for the company, currently overseeing 1 pending office action. Since there is only 1 pending office action in the entire portfolio, this examiner handles the totality of the company's active cases. The presence of only 1 distinct art unit and 1 distinct examiner indicates that the company is not currently managing multiple simultaneous patent applications. For a practitioner, the outcome of the portfolio's current standing rests on the interaction with LAFAVE, ELIZABETH ROSE.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAFAVE, ELIZABETH ROSE | 1 | 64.4% | +43.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253517 | MULTIPLEXED METHOD FOR ASSESSING GLOBAL OR GENOMIC LOCUS-SPECIFIC LEVELS OF CHROMATIN MODIFICATION | LAFAVE, ELIZABETH ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253517 | MULTIPLEXED METHOD FOR ASSESSING GLOBAL OR GENOMIC LOCUS-SPECIFIC LEVELS OF CHROMATIN MODIFICATION | LAFAVE, ELIZABETH ROSE | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18253517 | MULTIPLEXED METHOD FOR ASSESSING GLOBAL OR GENOMIC LOCUS-SPECIFIC LEVELS OF CHROMATIN MODIFICATION | LAFAVE, ELIZABETH ROSE | 1684 | §101§103§112 | Non-Final OA | — | Pending | Nov 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEpigenica AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elizabeth Rose Lafave has the most, with 1 of Epigenica AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
